Actavis buys three Roche drugs

Published: 15-Aug-2007

Roche has sold three of its pharmaceutical products to Actavis, a generic pharmaceutical company based in Iceland.


Roche has sold three of its pharmaceutical products to Actavis, a generic pharmaceutical company based in Iceland.

All product rights - with some territorial exceptions - for Bezalip and Rapilysin, both used in the cardiovascular field, and for the dermatology product Neotigason are being transferred to Actavis. In Latin America Roche will continue to distribute the products under a license of Actavis. In 2006 these three products had combined sales of CHF 140m (approximately Euro 85.5m).

The transactions are expected to close in stages in late 2007 and early 2008, subject to standard closing conditions. The financial terms were not disclosed.

Roche says that the agreements reflect its strategy of focusing on core products from its innovation-driven pharmaceutical and diagnostic divisions, two businesses with significant potential for high value creation.

You may also like